TrialFuture oncology (London, England)2026

TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors.

Hans Gelderblom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.